BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM. Hepatitis C Infection: A Systemic Disease. Clin Liver Dis. 2017;21:449-453. [PMID: 28689584 DOI: 10.1016/j.cld.2017.03.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Younossi ZM, Henry L. Quality of Life in Patients with Cirrhosis—Measurement and Clinical Impact. Curr Hepatology Rep 2018;17:15-21. [DOI: 10.1007/s11901-018-0385-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Younossi ZM. Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply. Aliment Pharmacol Ther 2018;47:537-8. [PMID: 29341278 DOI: 10.1111/apt.14481] [Reference Citation Analysis]
3 Younossi ZM, Henry L, P. Ong J, Tanaka A, Eguchi Y, Mizokami M, Lim Y, Dan YY, Yu M, Stepanova M. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther 2019;49:644-53. [DOI: 10.1111/apt.15131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
4 Adinolfi LE, Petta S, Fracanzani AL, Coppola C, Narciso V, Nevola R, Rinaldi L, Calvaruso V, Staiano L, Di Marco V, Marrone A, Pafundi PC, Solano A, Lombardi R, Sasso FC, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis 2020;296:40-7. [DOI: 10.1016/j.atherosclerosis.2020.01.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
5 Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
6 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511. [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026] [Cited by in Crossref: 905] [Cited by in F6Publishing: 751] [Article Influence: 226.3] [Reference Citation Analysis]
7 Saab S, Le L, Saggi S, Sundaram V, Tong MJ. Toward the elimination of hepatitis C in the United States. Hepatology 2018;67:2449-59. [PMID: 29181853 DOI: 10.1002/hep.29685] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
8 Goel A, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol 2018;33:2029-36. [PMID: 29864213 DOI: 10.1111/jgh.14301] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
9 Evon DM, Stewart PW, Amador J, Serper M, Lok AS, Sterling RK, Sarkar S, Golin CE, Reeve BB, Nelson DR, Reau N, Lim JK, Reddy KR, Di Bisceglie AM, Fried MW. . A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018;13:e0196908. [PMID: 30067745 DOI: 10.1371/journal.pone.0196908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
10 Wang JH, Chen CH, Chang CM, Feng WC, Lee CY, Lu SN. Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan. J Formos Med Assoc 2020;119:504-8. [PMID: 31350109 DOI: 10.1016/j.jfma.2019.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Bush H, Rafiq N, Younossi ZM. Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection. J Clin Gastroenterol 2019;53:262-8. [PMID: 30681638 DOI: 10.1097/MCG.0000000000001174] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Younossi ZM, Stepanova M, Reddy R, Manns MP, Bourliere M, Gordon SC, Schiff E, Tran T, Younossi I, Racila A. Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C. Liver Int 2019;39:54-9. [PMID: 29893462 DOI: 10.1111/liv.13900] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
13 Younossi ZM, Stepanova M, Henry L, Han KH, Ahn SH, Lim YS, Chuang WL, Kao JH, Nguyen KV, Lai CL, Chan HL, Wei L. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. J Viral Hepat. 2018;25:1429-1437. [PMID: 29974665 DOI: 10.1111/jvh.12965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
14 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
15 Stanciu C, Trifan A, Muzica C, Sfarti C. Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin Pharmacother 2019;20:379-84. [PMID: 30576256 DOI: 10.1080/14656566.2018.1560424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
16 Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018;25 Suppl 3:6-14. [PMID: 30398294 DOI: 10.1111/jvh.13005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
17 Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Pham T, Rathbun RC, Keast S, Nesser N, Farmer K, Skrepnek G. National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US. J Eval Clin Pract 2019;25:806-21. [PMID: 30485617 DOI: 10.1111/jep.13076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Ridruejo E, Mendizabal M, Silva MO. Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease: HCV in CKD stages 2-3. Hemodialysis International 2018;22:S97-S103. [DOI: 10.1111/hdi.12651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]